US pharma giant Merck & Co (NYSE: MRK) today announced positive top-line results from the pivotal Phase III MK-3475A-D77 ...
UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...
The company is confident that it is on to something special with its novel anti-growth differentiation factor-15 (GDF-15) ...
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, ...
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates.
VBI Vaccines is recalling PreHevbrio and shutting down operations amid bankruptcy. Despite FDA approval in 2021, the ...
Lindis Biotech has licensed Korjuny (catumaxomab) to Pharmanovia for malignant ascites, offering a targeted immune therapy ...
UK clinical-stage gene specialist Silence Therapeutics (Nasdaq: SLN) yesterday presented end-of-treatment data from its Phase ...
Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...
Aclaris Therapeutics has entered an exclusive licensing deal with Biosion for two antibodies, BSI-045B for atopic dermatitis ...
AbbVie says that Elahere is the first and only folate receptor alpha (FRÉ‘)-directed antibody drug conjugate (ADC) medicine ...
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Monday approved the medicine Filspari (sparsentan) from Vifor France to treat primary immunoglobulin A nephropathy (IgAN).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback